



**AMERICAN  
COLLEGE of  
CARDIOLOGY**

---

Heart House  
2400 N Street, NW  
Washington, DC 20037-1153  
USA

202.375.6000  
800.253.4636  
Fax: 202.375.7000  
[www.ACC.org](http://www.ACC.org)

---

*President*  
Mary Norine Walsh, MD, FACC

*Vice President*  
C. Michael Valentine, MD, FACC

*Treasurer*  
Robert A. Guyton, MD, FACC

*Secretary and Board of Governors Chair*  
B. Hadley Wilson, MD, FACC

*Trustees*  
Deepak L. Bhatt, MD, MPH, FACC  
Cathleen Biga, MSN, RN  
Paul N. Casale, MD, MPH, FACC  
Richard A. Chazal, MD, MACC  
Robert A. Guyton, MD, FACC  
Robert C. Hendel, MD, FACC  
Dipti Itchhaporia, MD, FACC  
Christopher M. Kramer, MD, FACC  
Michael J. Mack, MD, FACC  
Frederick A. Masoudi, MD, MSPH, FACC  
Andrew P. Miller, MD, FACC  
Jagat Narula, DM, MD, PhD, MACC  
Robert A. Shor, MD, FACC  
C. Michael Valentine, MD, FACC  
Mary Norine Walsh, MD, FACC  
Kim Allan Williams Sr., MD, MACC  
B. Hadley Wilson, MD, FACC

*Chief Executive Officer*  
Shal Jacobovitz

---

*The mission of the American College  
of Cardiology and the American  
College of Cardiology Foundation  
is to transform cardiovascular care  
and improve heart health.*

June 9, 2017

Dear Managing CV Disease Risk in Diabetes Roundtable participants,

Thank you for accepting the invitation to participate at this Roundtable. As an esteemed participant, you are joining representatives from several medical specialty societies, industry, health systems, and other stakeholder groups to discuss key questions and issues regarding the management of CV disease in diabetic patients with a focus on the emergence of new cardioprotective antidiabetic agents. Your engagement in this initiative will help the American College of Cardiology (ACC) as we make strides toward improving patient outcomes.

The purpose of this effort is to facilitate a greater understanding of real-life challenges faced by patients, caregivers, clinicians, payers and health systems in incorporating newer agents for improved outcomes in diabetic patients at high risk for or established CV disease. The goal is to draw on the collective experience and wisdom of participants to identify issues and inform the development of ACC practical guidance for clinicians in areas where evidence may be limited, new and evolving, or lack sufficient data to fully inform clinical decision making.

The aim of this meeting is not to reach consensus; we aim to uncover the obstacles faced and hope to explore ideas of how the ACC can better serve clinicians and patients in managing CV disease risk in diabetes. Your valuable input will help to steer our work to support the broader community caring for patients and improve patient outcomes.

As you will see in the enclosed agenda, the day will be organized by three sessions with brief thought provoking presentations to introduce key topics. Each session will direct participants to work together in small groups to discuss several questions that are provided for you in this book, and then will share their combined thoughts with the full group.

In preparation for the Roundtable, we have assembled briefing materials for your review. Given the difference in participants' backgrounds, we have selected what we believe to be the most important materials for everyone to be familiar with at the meeting, including the agenda, discussion questions and articles of interest. We hope that you will familiarize yourself with these materials before the meeting to encourage a productive discussion. We encourage all participants to consider the discussion questions in advance of the meeting, and recommend that you discuss with your colleagues to collect additional perspectives and thoughts to bring with you to the Roundtable.

If you have any questions, please contact Ashleigh Covington at [acovington@acc.org](mailto:acovington@acc.org) or 202.375.6444.

We look forward to your participation and contribution to the Managing CV Disease Risk in Diabetes Roundtable.

Sincerely,

**Mikhail Kosiborod, MD, FACC**  
Co-Chair, Managing CV Disease  
Risk in Diabetes Roundtable

**Laurence S. Sperling, MD, FACC**  
Co-Chair, Managing CV Disease  
Risk in Diabetes Roundtable